July 21, 2008

NanoViricides, Inc. Added to the Ludlow Biotech Index

NanoViricides, Inc. (OTC BB: NNVC.OB) a development stage company that is creating special purpose nanomaterials for the treatment of viral infections, today announced that the company has been added to the Ludlow Biotech Index.

Tom Bustamante, the Managing Partner of Ludlow BioVentures commented, "NanoViricides utilizes creative and unique nanomaterials for targeting and destroying viruses. The company's nanoviricides(TM) drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. NanoViricides, Inc. is thus creating treatments that need to be given only to patients that contract a viral disease, as opposed to vaccines, which must be given to substantially the entire population to prevent the occurrence of an epidemic. Nanoviricide drugs form a novel class of drugs, that is complementary to other existing viral therapies. This unique approach makes NNVC an interesting play in the field of viral therapy, and should provide for additional depth to our biotechnology stock index."

The Ludlow Biotech Index is a diverse basket of biotechnology stocks, that includes well established biotech stocks such as Amgen, Biogen-Idec, and Genzyme. This index provides institutional investors a means to track and trade a basket of small cap biotechnology stocks, with reduced risk through diversification. The Ludlow Biotech Index is owned and operated by Ludlow Capital Group, Inc.

For additional information on the Ludlow Biotech Index and its components visit http://www.ludlowcapital.com/indices/biotech/


NanoViricides, Inc. is not a client of Ludlow BioVentures. NanoViricides, Inc. has not paid any compensation to Ludlow for inclusion of NNVC in the Ludlow Biotech Index.

About Ludlow BioVentures:Based in New York City, Ludlow BioVentures is a venture capital and research advisory firm with a specific focus on the biotechnology sector. The goal of the firm is to promote investments into biotech ventures worldwide. Ludlow BioVentures owns and operates the Ludlow Biotech Index, which tracks a wide basket of US traded large and small cap biotechnology stocks. www.ludlowcapital.com/bioventures/

About NanoViricides:

NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for treatment of viral infections. The Company's novel nanoviricide(TM) class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H5N1 bird flu, seasonal influenza, HIV, EKC, hepatitis C, rabies, dengue fever, and Ebola virus, among others.

This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Forward-looking statements involve risks and uncertainties. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward looking statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance, or achievements of the company to be different from those expressed or implied including the success of the Company's research and development efforts, the availability of adequate financing, the successful and timely completion of clinical studies and the uncertainties related to the regulatory process, described in the "Management's Discussion and Analysis" section of the Company's Form 10-KSB and other reports and filings with the Securities and Exchange Commission.